You are now leaving XTANDI.com
The website you are about to visit is not owned or controlled by Astellas. Astellas are not responsible for the information or services on this site.
NORTHBROOK, Ill., Sept. 2, 2014 /PRNewswire/ -- Astellas has appointed James Kellerman as the vice president of intellectual property (IP) in the Americas. Kellerman will report directly to Linda Friedman, senior vice president & general counsel at Astellas. In his new role, Kellerman will lead a team of patent attorneys to partner with the business and manage the region's intellectual property matters, coordinating closely with his global colleagues.
"I am very pleased to welcome Jim to Astellas. Jim brings a broad perspective of the industry and a breadth of pharmaceutical IP experience to his new position. He will be a strong leader for our IP group," said Friedman.
Kellerman has more than 25 years of broad IP and industry experience in the pharmaceutical industry as well as experience in other roles early in his career. For the past 11 years, Kellerman has worked at GlaxoSmithKline in the IP department in the US as well as in China. Prior to that he was the corporate intellectual property counsel for Sepracor Inc. Kellerman received his B.S. Pharmacy from the University of Cincinnati, College of Pharmacy and his law degree from the Franklin Pierce Law Center in Concord, New Hampshire.
About Astellas
Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information on Astellas, please visit our website at www.astellas.us. You can also follow us on Twitter at @AstellasUS.
Photo - http://photos.prnewswire.com/prnh/20140902/142153
Logo - http://photos.prnewswire.com/prnh/20140416/84970
SOURCE Astellas
Get only the email alerts you want.
For media inquiries and reporter requests, please email us at corporate.communications@us.astellas.com.
Our communications team will respond to verified media requests within 24-48 hours as appropriate.
If you are not a reporter and need assistance, please visit our contact us page that includes information for patients, healthcare providers and researchers.
This website is intended for U.S. residents only. This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including those under development. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider.
The site uses cookies to provide you with a more responsive and personalized service and to analyze site traffic. By using this site, you accept our use of cookies as described in our privacy policy. Please read our privacy policy for more information on the cookies we use, the processing of your personal data and how to delete or block the use of cookies.